SPARC1104 modified dose regimen I — Competitive Intelligence Brief

SPARC1104 modified dose regimen I (SPARC1104 modified dose regimen I) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune checkpoint inhibitor. Area: Oncology.

phase 3 Immune checkpoint inhibitor PD-1/PD-L1 Oncology Small molecule

Target snapshot

SPARC1104 modified dose regimen I (SPARC1104 modified dose regimen I) — Sun Pharma Advanced Research Company Limited. SPARC1104 modified dose regimen I is a drug that targets the PD-1/PD-L1 pathway.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SPARC1104 modified dose regimen I TARGET	SPARC1104 modified dose regimen I	Sun Pharma Advanced Research Company Limited	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
Pf-06823859	pf-06823859	Pfizer	marketed	Monoclonal Antibody	PD-1/PD-L1
Pf-06865571	pf-06865571	Pfizer	marketed	Monoclonal antibody	PD-1/PD-L1 pathway
Investigational products administration	Investigational products administration	Assistance Publique - Hôpitaux de Paris	phase 3	Immune checkpoint inhibitor	PD-1/PD-L1
TQB3616 capsule	TQB3616 capsule	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1
HyperAcute-Pancreas Immunotherapy	HyperAcute-Pancreas Immunotherapy	NewLink Genetics Corporation	phase 3	Cancer immunotherapy vaccine combination	Tumor-associated antigens (pancreatic cancer cell surface antigens); PD-1/PD-L1 pathway
TQB2303	TQB2303	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	PD-1/PD-L1 inhibitor	PD-1/PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune checkpoint inhibitor class)

1. Sun Pharma Advanced Research Company Limited · 2 drugs in this class
2. Brenda Cooper, MD · 1 drug in this class
3. Grace Therapeutics Inc. · 1 drug in this class
4. EMS · 1 drug in this class
5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
6. Glycotope GmbH · 1 drug in this class
7. Bristol-Myers Squibb · 1 drug in this class
8. HK inno.N Corporation · 1 drug in this class
9. Hanlim Pharm. Co., Ltd. · 1 drug in this class
10. Assistance Publique - Hôpitaux de Paris · 1 drug in this class